Ella C Troy
YOU?
Author Swipe
View article: Results of a phase I trial with Haploidentical <scp>mbIL</scp>‐21 ex vivo expanded <scp>NK</scp> cells for patients with multiply relapsed and refractory <scp>AML</scp>
Results of a phase I trial with Haploidentical <span>mbIL</span>‐21 ex vivo expanded <span>NK</span> cells for patients with multiply relapsed and refractory <span>AML</span> Open
Natural killer (NK)‐cells have potent anti‐tumor effects, yet it remains unclear if they are effective for patients with relapsed acute myeloid leukemia (AML). In a phase I clinical trial, we treated 12 patients (median age 60 years) with …